New drug HW241045 takes first step: safety check in healthy volunteers
NCT ID NCT07448194
First seen Mar 13, 2026 · Last updated May 06, 2026 · Updated 11 times
Summary
This early-phase study tests the safety and tolerability of a single dose of HW241045 in 56 healthy adults aged 18-55. Participants are randomly assigned to receive either the drug or a placebo, and researchers monitor for side effects. The goal is to gather initial safety data before testing the drug in patients with a lung condition called IPF.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Union Medical College Hospital
RECRUITINGBeijing, 100730, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.